Literature DB >> 32923913

FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia.

Ying Liu1, Xiaoli Mi2, Ramya Gadde1, Qi Gao1, Wenbin Xiao1, Yanming Zhang3, Rayma Benayed4, Maria Arcila4, Ahmet Dogan1, Mark B Geyer2,5, Mikhail Roshal1.   

Abstract

Entities:  

Year:  2020        PMID： 32923913      PMCID： PMC7469588          DOI： 10.1200/PO.19.00402

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  19 in total

1.  Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.

Authors:  Bartlomiej M Getta; Sean M Devlin; Ross L Levine; Maria E Arcila; Abhinita S Mohanty; Ahmet Zehir; Martin S Tallman; Sergio A Giralt; Mikhail Roshal
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-15       Impact factor: 5.742

2.  Myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Authors:  Paolo Strati; Guilin Tang; Dzifa Y Duose; Saradhi Mallampati; Rajyalakshmi Luthra; Keyur P Patel; Mohammad Hussaini; Abu-Sayeef Mirza; Rami S Komrokji; Stephen Oh; John Mascarenhas; Vesna Najfeld; Vivek Subbiah; Hagop Kantarjian; Guillermo Garcia-Manero; Srdan Verstovsek; Naval Daver
Journal:  Leuk Lymphoma       Date:  2017-11-09

3.  Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.

Authors:  Mrinal M Patnaik; Naseema Gangat; Ryan A Knudson; Jeannette G Keefe; Curtis A Hanson; Animesh Pardanani; Rhett P Ketterling; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2010-04       Impact factor: 10.047

4.  Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

Authors:  M S Khodadoust; B Luo; B C Medeiros; R C Johnson; M D Ewalt; A S Schalkwyk; C D Bangs; A M Cherry; S Arai; D A Arber; J L Zehnder; J Gotlib
Journal:  Leukemia       Date:  2015-06-09       Impact factor: 11.528

Review 5.  8p11 myeloproliferative syndrome: a review.

Authors:  Courtney C Jackson; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Hum Pathol       Date:  2010-04       Impact factor: 3.466

6.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

Review 7.  Myeloid neoplasms with eosinophilia.

Authors:  Andreas Reiter; Jason Gotlib
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

8.  Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Authors:  Mingqiang Ren; Haiyan Qin; Eiko Kitamura; John K Cowell
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 9.  Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.

Authors:  Kento Umino; Shin-Ichiro Fujiwara; Takashi Ikeda; Yumiko Toda; Shoko Ito; Kiyomi Mashima; Daisuke Minakata; Hirofumi Nakano; Ryoko Yamasaki; Yasufumi Kawasaki; Miyuki Sugimoto; Chihiro Yamamoto; Masahiro Ashizawa; Kaoru Hatano; Kazuya Sato; Iekuni Oh; Ken Ohmine; Kazuo Muroi; Yoshinobu Kanda
Journal:  Hematology       Date:  2018-02-28       Impact factor: 2.269

Review 10.  Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.

Authors:  Barbara J Bain; Sarah H Fletcher
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.